AstraZeneca and CrystalGenomics Form Research Collaboration to Develop Novel Anti-lnfective Treatments

摘要

AstraZeneca and CrystalGenomics announced that they have entered into a research collaboration to discover and develop a novel anti-infective for use as a potential antibacterial agent. Under the terms of this agreement, Korea-based CrystalGenomics will receive research funding from AstraZeneca for two years. CrystalGenomics will also be eligible to receive future milestones and royalty payments associated with development and commercialization of a drug candidate. Further financial terms of the agreement were not disclosed.